Natera, Inc.
NTRANatera is a diagnostics company specializing in cell-free DNA (cfDNA) testing and bioinformatics technology.
Earnings
Next report
Aug 6, 2026 (In 3 weeks)Valuation & ratios
Segments
Competitors
By market cap
By revenue growth
Profile
Natera is a diagnostics company specializing in cell-free DNA (cfDNA) testing and bioinformatics technology. The company leverages proprietary molecular assays and statistical algorithms to provide high-accuracy genetic testing across oncology, women’s health, and organ health. Its core value proposition is transforming disease management through non-invasive, personalized diagnostics that inform earlier and more targeted clinical interventions.
Natera is a market leader in the U.S. NIPT space by volume and a pioneer in personalized tumor-informed MRD testing. The company maintains a strong intellectual property portfolio and extensive peer-reviewed clinical evidence to support its market position.
Questions, answered.
- What is Natera, Inc.'s market cap?
- Natera, Inc. (NTRA) has a market capitalization of $39.3B and trades on NASDAQ.
- What is Natera, Inc.'s revenue and profitability?
- Natera, Inc. generated $2.5B in trailing twelve-month revenue with a net loss of $340.5M, representing a net margin of -14.6%. Gross margin stands at 42.9%, with free cash flow of $104.5M. These figures are based on the Q1 2026 filing.
- Who are Natera, Inc.'s competitors?
- Natera, Inc.'s key competitors include Myriad Genetics, Inc., Guardant Health, Inc., CareDx, Inc., and others. These companies compete in similar markets and product categories.
- Who does Natera, Inc. partner with?
- Natera, Inc.'s notable partners include United Healthcare, Aetna, Humana, and others.
- What subsidiaries does Natera, Inc. have?
- Natera, Inc.'s subsidiaries include Foresight Diagnostics.
- Where is Natera, Inc. headquartered?
- Natera, Inc. is headquartered in United States of America and employs approximately 3,293 people. It has been publicly traded since 2015.
